VolitionRx Limited (VNRX)

Market Cap	67.81M
Revenue (ttm)	1.32M
Net Income (ttm)	-23.32M
Shares Out	107.60M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,838
Open	0.6610
Previous Close	0.6561
Day's Range	0.6258 - 0.6700
52-Week Range	0.3951 - 0.9400
Beta	1.27
Analysts	Strong Buy
Price Target	3.50 (+455.38%)
Earnings Date	Nov 13, 2025

About VNRX

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes; Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment r...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Cameron Reynolds
• Employees: 85
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: VNRX
• Website: https://volition.com

Financial Performance

In 2024, VolitionRx's revenue was $1.23 million, an increase of 59.10% compared to the previous year's $775,302. Losses were -$26.97 million, -23.65% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for VNRX stock is "Strong Buy." The 12-month stock price target is $3.5, which is an increase of 455.38% from the latest price.

Price Target

$3.5

(455.38% upside)

Analyst Consensus: Strong Buy